Include All CSL Behring Country Sites

Canadian Products

We offer a wide range of plasma-derived and recombinant therapeutic products including a variety of products used in the hospital setting for critical care, for primary immunological disorders, and as thrombolytic agents.

The information provided herein is solely for use by physicians and healthcare professionals in Canada. The products listed may not have been approved in other countries and may not be available everywhere.

Transplant Medicine



Cytomegalovirus Immune Globulin Intravenous (HUMAN) (CMV-IGIV)
Indicated for attenuation of primary (1°) Cytomegalovirus disease associated with kidney transplantation
Product Monograph



Antihemophilic Factor VIII (Recombinant), SingleChain
A recombinant DNA-derived, antihemophilic factor indicated in adults and children with hemophilia A (congenital Factor VIII deficiency) for:

  • Control and prevention of bleeding episodes,
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes,
  • Perioperative management of bleeding (surgical prophylaxis).

Safety and efficacy data are not available for previously untreated patients (PUPs).
AFSTYLA is not indicated for treatment of Von Willebrand disease.
Product Monograph



Factor XIII Concentrate, Human
Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in patients with congenital Factor XIII deficiency
Product Monograph



Fibrinogen concentrate (Human), FCH
Indicated for treatment of congenital fibrinogen deficiency which comprises congenital
afibrinogenemia and hypofibrinogenemia.
Product Monograph



Antihemophilic Factor/von Willebrand Factor Complex (Human)
Indicated for treatment of classical hemophilia (hemophilia A) and von Willebrand Disease (vWD)
Product Monograph


Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
An antihemophilic factor indicated in patients with hemophilia B (congenital FIX deficiency) or Christmas disease for:

  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
  • Control and prevention of bleeding episodes
  • Control and prevention of bleeding in the perioperative setting

Studies described in this monograph have been performed only in previously treated patients (PTPs).
Product Monograph

Critical Care & Immunology

Critical Care


Alburex® 5, Alburex® 25

Albumin (Human) 5% Solution, 25% solution
Indicated for restoring and maintaining circulating blood volume, in Shock, Burns, Hypoproteinemia with or without edema
Product Monograph

Berinert® 500 / Berinert® 1500

Human C1 esterase inhibitor
Indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) of moderate to severe intensity
Product Monograph

Beriplex® P/N 500 / Beriplex® P/N 1000

Human prothrombin complex
Indicated in adult patients who require treatment and perioperative prophylaxis of bleeding in case of acquired deficiency of the prothrombin complex coagulation factors, when rapid correction of the deficiency is required 
Product Monograph




Subcutaneous Immune Globulin (Human), 20% Solution for injection
Indicated for Primary & Secondary Immune deficiency requiring replacement therapy
Product Monograph



Immune Globulin Intravenous (Human) 10% solution 
Indicated for treatment of patients with primary immune deficiency (PID), secondary immune deficiency (SID) and immune thrombocytopenic purpura (ITP) as well as immunomodulation in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Product Monograph